Psychedelic
Integration
Supporting your journey—before, during, and after.
Integration,
Not Administration
After decades of prohibition, psychedelic medicines are undergoing rigorous clinical research for treatment-resistant mental health conditions. The evidence is mounting—but regulatory approval is still evolving.
Our role is not to provide these substances. Instead, we offer something equally valuable: expert medical support for those who choose to explore these experiences on their own.
Using a compassionate, non-directive harm-reduction approach, we help patients prepare for, understand, and integrate their experiences— maximizing potential benefits while minimizing risks.
Important Notice
We do not provide or prescribe psychedelics. All classical psychedelics—including psilocybin, MDMA, LSD, and DMT—remain Schedule I controlled substances under federal law.
We do not refer patients to underground providers or encourage illegal activities. Our services focus exclusively on preparation, education, and post-experience integration therapy.
The Evolving Landscape
The path to FDA approval is complex but progressing. Here's where things stand.
Psilocybin
Phase 3 trials for treatment-resistant depression are progressing. FDA approval projected for late 2026 or early 2027. Oregon and Colorado have established state-supervised programs outside the federal framework.
AdvancingMDMA
FDA did not approve the initial application for PTSD treatment (August 2024) citing trial methodology concerns. New Phase 3 trial underway; resubmission expected mid-2026.
DelayedHow We Support You
Using a compassionate, non-directive harm-reduction approach, we help patients prepare for, understand, and integrate their experiences.
Pre-Experience Preparation
- •Comprehensive medical evaluation
- •Review of medications and drug interactions
- •Psychological readiness assessment
- •Cardiac testing and risk stratification
- •Intentions, goals, and set/setting guidance
Integration Therapy
- •Processing and meaning-making sessions
- •Therapeutic support with trained clinicians
- •Journaling and reflection guidance
- •Translating insights into lasting change
- •Ongoing psychotherapy as needed
Harm Reduction Education
- •Physiological effects and risks
- •Contraindications and safety protocols
- •Substance testing and purity concerns
- •Set and setting optimization
- •Managing difficult experiences
Expertise in
Psychedelic Science
Our Medical Director, Dr. Paul Abramson, was an early graduate of the Certificate in Psychedelic Therapies and Research (CPTR) program at the California Institute of Integral Studies in San Francisco.
He has been involved in psychedelic science for over 20 years, and has provided support to the clinical trial team at UCSF studying group therapy combined with psilocybin sessions for demoralization in long-term AIDS survivors.
This combination of academic training, research involvement, and clinical experience informs our approach to integration therapy.
Training & Experience
CIIS Certificate
Psychedelic Therapies and Research
20+ Years
Involvement in psychedelic science
UCSF Research
Clinical trial support for psilocybin studies
Begin a Confidential Conversation
Whether you're seeking integration support, harm reduction education, or preparation guidance, our team is here to help. All inquiries are handled with complete discretion.